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Abstract Hemorphin generation by mice peritoneal macro-
phages has been recently reported, nevertheless no conclusive
data exist to localize clearly the macrophage proteolytic activity
implicated in their generation. Because lysosomes are believed to
be the main site of degradation in the endocytic pathway, we have
studied their potential implication in the generation of hemor-
phins from hemoglobin. When this protein is submitted to
purified rat liver lysosomes, an early generation of hemorphin-7-
related peptides, detected by a radioimmunoassay, was observed.
These peptides seemed to be relatively stable during the first
hours of hydrolysis.
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1. Introduction
In 1986, Brantl et al. [1] detected from a proteolytic treat-
ment of hemoglobin a series of peptides, with an opioid-like
activity, called hemorphins. This study was of great impor-
tance because it followed many other previous discoveries of
biologically active peptides reproducing amino acid sequences
of K- or L-globin chains [2]. Among these peptides, the best
known, kyotorphin and neokyotorphin [3], corresponded re-
spectively to the 140^141 and 137^141 C-terminal sequences
of K-globin. Since the ¢ndings of Brantl et al., systematic
studies of peptide composition of various tissue extracts re-
sulted in a great number of new peptides with structure
mainly originating from K- or L-globin chains [2]. In addition,
some of these hemoglobin-derived peptides were often found
to coexist with various pathologies such as human lung ad-
enocarcinoma [4], Alzheimer’s disease [5], Hodgkin’s disease
[6] and brain ischemia [7] and even subsequently to physical
exercise like long distance running [8]. In the latter study, it
was noteworthy that the plasma level of the released hemor-
phin-7 exceeded that of L-endorphins by a factor of about
1000. Finally, an attractive feature of the hemorphins is their
link to the L-endorphin system: the hemoglobin-derived
opioid peptides have the capacity to release the classical
opioid peptides from the pituitary into the circulatory system
[9].
It was then becoming clear that hemoglobin, besides its
primordial function as an oxygen carrier, could serve in
vivo as a powerful source of bioactive peptides playing a
profound role in homeostasis [2]. This assessment could be
probably closely connected with a suggestion of Carraway et
al. [10] about the existence of a putative endogenous process-
ing which generates neurotensin and enkephalin-related pep-
tides in blood circulation from plasma proteins. The main
question arising from the above-mentioned considerations
concerns the possible way of natural generation of hemor-
phins in the organism.
In a previous study [11], two opioid peptides, corresponding
to the sequence 32^40 (VV-hemorphin-7) and 31^40 (LVV-
hemorphin-7) of the L-chain of bovine hemoglobin, were iso-
lated in vitro from a bovine hemoglobin peptic hydrolysate.
According to the fundamental knowledge of the physiology of
macrophages and their role in the cellular protein catabolism
and/or in the in£ammatory process, we have investigated the
appearance of hemorphins when hemoglobin is in the pres-
ence of mice peritoneal macrophages [12]. It was then clearly
demonstrated that under these conditions, VV-hemorphin-7
could be released from globin. Nevertheless, no conclusive
data exist to localize clearly the origin of the proteolytic ac-
tivity responsible for hemorphin release, even if subsequent
studies suggested that hemorphin generation could be the re-
sult of an acidic protease cleavage [12,13].
The aim of the present study was to investigate the involve-
ment of the macrophage proteolytic complexes in hemorphin
generation. For this purpose, rat hepatic lysosomes were pu-
ri¢ed in order to expose directly hemoglobin to lysosomal
enzymes. Moreover, analytical tools previously developed in
our laboratory to identify peptides from complex proteolytic
mixtures have been applied: reversed phase high performance
liquid chromatography (RP-HPLC) on-line with spectral scan
analysis [14], amino acid analysis [15] and mass spectrometry
analysis [16]. A speci¢c radioimmunoassay (RIA) against the
C-terminal part of VV-hemorphin-7, recently perfected and
validated [17] was also performed to verify the patterns of
generated hemorphins.
2. Materials and methods
2.1. Materials and chemicals
HPLC analyses were performed with a Waters 600 automated gra-
dient controller-pump module, a Waters wisp 717 automatic sampling
device and a Waters 996 photodiode array detector (Milford, MA,
USA). Deltapak C18 column was purchased from Waters (Milford,
MA, USA). The Millenium software was used to plot, acquire and
treat spectral and chromatographic data.
Trisodium citrate was from Prolabo and sucrose from Acros Or-
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ganics. HEPES, bovine serum albumin (BSA) and metrizamide (cen-
trifugation grade) were from Sigma. Picotag sample diluent and eluent
A were from Waters (Millipore Corporation, Milford, MA, USA).
Amino acid standard H and phenyl isothiocyanate (PITC) were
from Pierce (Rockford, IL, USA). Acetonitrile was of HPLC grade
and aqueous HPLC eluents were degassed with helium during analy-
sis. LVV-hemorphin-7, VV-hemorphin-6, VV-hemorphin-7 and hem-
orphin-7 were synthesized by Altergen (Schiltigheim, France). Prior to
use, synthetic peptides were puri¢ed by HPLC. Synthetic VV-hemor-
phin-7 was iodinated according to the Hunter and Greenwood proce-
dure [18]. Chemicals and solvents were of the best analytical quality
available.
2.2. Methods
2.2.1. Preparation of rat liver lysosomal fractions. Lysosomes were
obtained from rat liver as previously described [19,20]. Brie£y, male
Wistar rats (200^250 g), starved overnight, were anesthetized with
chloroform and decapitated. The livers were immediately removed,
chilled in ice-cold 0.25 M sucrose, and homogenized in the same
medium by means of a Te£on pestle in a Potter Thomas tissue grind-
er. The homogenate was made up to a volume of 7 ml/g of liver and
¢ltered on two layers of cheesecloth. After the centrifugation of the
¢ltrate (2500Ug, 10 min, 4‡C), the pellet (C1) was discarded and the
remaining supernatant (S1) was centrifuged at 10 000Ug for 20 min at
4‡C. The resulting pellet was suspended in sucrose and centrifuged as
previously. The ¢nal pellet (C2) was loaded on the bottom of a dis-
continuous metrizamide gradient (adjusted to pH 7.0 with NaOH)
and centrifuged 2 h at 95 000Ug at 4‡C (Beckman ultracentrifuge,
rotor SW 28.1). Five di¡erent fractions were obtained: the 19.8^
24.5 (F1), 24.5^26.3 (F2), 26.3^32.8 (F3) metrizamide interfaces and
the bottom layer named F5. The fraction F4 corresponds to the 32.8%
metrizamide solution. The fractions were collected from the gradient,
diluted ¢ve times with 0.25 M sucrose and centrifuged at 37 000Ug
for 10 min in the Beckman centrifuge (rotor SW 28.1). Pellets were
then resuspended in a small volume of 0.1 M phosphate bu¡er, pH 7.3
and stored at 320‡C until use.
Small aliquots of homogenate, pellets, supernatants and selected
fractions of the metrizamide gradient were kept for both mitochon-
drial and lysosomal enzymes and protein content determinations.
Qualitative evaluation of succinic dehydrogenase, a mitochondrial
marker, and the degree of puri¢cation of lysosomes, estimated by
the speci¢c acid phosphatase activity in the fraction relative to the
original homogenate, were estimated according to Tsou et al. [21]. The
protein contents were determined by the Lowry procedure [22].
2.2.2. Hemoglobin proteolysis. Bovine hemoglobin was prepared
from erythrocytes as described previously [17]. Lysosomes (200 Wg
of protein) from fraction F3 were incubated with hemoglobin (0.2%
w/v) in a ¢nal volume of 500 Wl of 4 mM sodium citrate bu¡er, pH 4.5
at 37‡C. Before the incubation, lysosomes were disrupted by freezing
and thawing six times (broken lysosomes). Incubations were achieved
during 1, 5, 10, 30, 60, 120 and 240 min.
The reactions were stopped by boiling incubation mixtures during
20 min. Residual hemoglobin was discarded by centrifugation (5000
rpm, 15 min), supernatants were collected by ¢ltration using a 0.22
Wm pore membrane and stored at 320‡C until their chromatographic
analysis. Two controls were carried out: hemoglobin alone and lyso-
somes alone were submitted to the same procedures of incubation and
analysis.
2.2.3. Chromatographic and spectral scan analysis procedures. In
order to characterize VV-hemorphin-7 immunoreactive peptides,
supernatants of hemoglobin hydrolysates were separated by RP-
HPLC using a Deltapak C18 column (300U3.9 mm i.d.) with a linear
gradient of acetonitrile (eluent A: 10 mM ammonium acetate bu¡er,
pH 6.0; eluent B: acetonitrile) from 15% to 40% B for 30 min after an
initial isocratic step (15% B) over a period of 5 min. The £ow rate was
1 ml/min. Aliquots (100 Wl) of each supernatant from 1 to 240 min
incubation were injected through the HPLC column. Fractions (1 ml
each) were automatically collected, lyophilized and reconstituted in
RIA bu¡er (HEPES bu¡er) in order to be assayed by radioimmuno-
assay.
Continuous UV absorbance spectral scans were performed, between
190 and 300 nm, during chromatographic acquisition. Spectrum
matching results (i.e. comparison between spectra of each eluted
peak and a library spectrum of hemorphins) were expressed as match
angle (MA) and match threshold (MT). Spectral scan procedure has
been extensively used in previous studies [13,14].
2.2.4. Determination of VV-hemorphin-7 peptides by radioimmunoas-
say. Standard, samples, tracer and antiserum were diluted in RIA
bu¡er. Radioimmunoassay procedure for VV-hemorphin-7 was based
on the precipitation with polyethylene glycol (PEG) and was con-
ducted as described in a previous paper [17]. Brie£y, the fractions
from the RP-HPLC stage were lyophilized and reconstituted in 1 ml
of RIA bu¡er. A 100 Wl aliquot of the fraction or standard, 100 Wl IG-
C2 antiserum (¢nal dilution 1/125 000) and 100 Wl iodinated peptide
(5000 cpm) were incubated for 40 h at 4‡C. After precipitation with
PEG, the radioactivity of the pellet was measured and the bound/total
ratio (B/T) calculated.
2.2.5. Amino acid analysis. Amino acids were analyzed using a
Waters Picotag Work Station. Peptide hydrolysis was achieved with
constant boiling HCl containing 1% phenol, for 24 h at 100‡C. Pre-
column derivatization of amino acids with phenyl isothiocyanate and
HPLC separation of derivatized amino acids on a Waters RP-Picotag
column (150U3.9 mm i.d.) were performed according to Bidlingmeyer
et al. [23]. The £ow rate was 1 ml/min and the detection was carried
out at 254 nm.
2.2.6. MALDI (matrix assisted laser desorption ionization) mass
spectrometry analysis. MALDI mass spectra were measured on a
re£ectron-type Vision 2000 time-of-£ight mass spectrometer (Finnigan
MAT, Bremen, Germany). Samples were mounted on an x^y move-
able stage, allowing irradiation of selected sample areas. A nitrogen
laser with an emission wavelength of 337 nm and a pulse duration of
3 ns was used. Spectra were recorded in the positive ion mode and
accelerated to an energy of 5 keV before entering the £ight tube. Ions
were post-accelerated, for detection, to an energy of 5 keV. Samples
were prepared by mixing, directly on the target, 1 Wl of the peptides
diluted to a concentration of 2^8 pmoles/Wl and 1 Wl of 2,5-dihydrox-
ybenzoic acid (DHB) matrix solution (12 mg/ml dissolved in CH3OH-
H2O (70:30)). The samples were allowed to dry for 3^4 min at room
temperature. Electrospray mass spectra were acquired on a Micro-
mass Quattro II triple-quadrapole mass spectrometer operating with
an API ion source in positive ion electrospray mode. Peptide samples
were diluted into acetonitrile/0.2% formic acid (1:1 by volume), to a
concentration of 10 pM/Wl and infused at 3 Wl/min. Spectra were
scanned with a cone voltage of 35 V.
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Table 1
Protein content and activities of a lysosomal enzyme in homogenate, pellet C2 from rat liver and in di¡erent fractions (F1^F5) obtained after
centrifugation of C2 in a discontinuous metrizamide gradient
Protein (g) Acid phosphatase
(units/mg protein)
Puri¢cation degreea Yieldb
Homogenate 7.78 0.0603
C2 0.882 0.177
F1 0.0037 0.657 10.9 0.5
F2 0.0045 1.116 18.5 1.1
F3 0.0217 0.863 14.31 4
F4 0.01346 0.7055 11.7 2
F5 0.757 0.0467 0.774 7.5
aResults are given in relative speci¢c activity, i.e. speci¢c activity found in the fraction/speci¢c activity measured in the homogenate.
bResults are given in total activity, i.e. total activity found in the fraction/total activity measured in the homogenate.
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3. Results
In order to assess the role of lysosomes in the generation of
hemorphins from hemoglobin, they were prepared from rat
liver according to the procedure of Wattiaux et al. [19]. As
estimated by the acid phosphatase activity, lysosomes were
markedly puri¢ed in fractions F1, F2, F3 and F4 of the met-
rizamide gradient (Table 1). The degree of puri¢cation of
lysosomes (based on acid phosphatase activity) recovered in
fraction F3, relative to the original homogenate was 14.31-fold
and the yield 4% (total activity in the fraction/total activity in
the homogenate). Relative to the fraction F2, which exhibited
the better speci¢c activity (1.116), fraction F3 constituted the
best compromise between both a good speci¢c activity (0.863)
and yield (4% vs. 1.1% for F2). The qualitative evaluation of
the mitochondrial marker demonstrated that F3 was free of
mitochondria (data not shown).
In order to determine if a possible way of degradation of
hemoglobin by macrophages could take place in lysosomes
[12], we have submitted hemoglobin to broken lysosomes
from fraction F3. A kinetics of degradation of hemoglobin
was carried out. The resulting hydrolysates were analyzed
by RP-HPLC and collected fractions (1 ml) were assayed
for their content in VV-hemorphin-7 by RIA. Chromato-
grams from proteolysis of hemoglobin after 1 and 240 min
of incubation are displayed in Fig. 1. As soon as 1 min of
hydrolysis (Fig. 1A), VV-hemorphin-7-related immunoreac-
tive material (VVH7-i.r.) is released. The immunoreactive ma-
terial was mainly detected in three fractions, named fraction
A, fraction B and fraction C. The weak immunoreactivity
detected between 32 and 40 min has not been precisely studied
and could correspond to N-terminal extended hemorphin-7-
related peptides previously described by Glaºmsta et al. [24].
After 240 min of hydrolysis (Fig. 1B), few amounts of pep-
tides were detected at 280 nm and a very low VVH7-i.r. was
observed in fractions A, B and C.
Immunoreactive material detected in the hydrolysate was
undoubtedly the result of the co-incubation of hemoglobin
with lysosomes since when both hemoglobin and/or lysosomes
were incubated alone, no immunoreactive material was re-
leased whatever the incubation time (data not shown).
The level of VVH7-i.r. in fractions A, B and C during
hydrolysis is presented in Fig. 2. The VVH7-i.r. found in
fraction A increased rapidly, reached a maximum at 5 min
and began to decrease after 60 min. After 240 min of incuba-
tion, a very small amount of VVH7-i.r. was detected. The
same evolution was observed for the other two fractions (B
and C), nevertheless, the immunoreactive material present in
these fractions was always much lower than in fraction A.
Synthetic hemorphins were loaded on the RP-HPLC col-
umn, and their chromatographic parameters (retention time,
MA and MT) compared with those obtained for fractions A,
B and C (Table 2). According to this comparative study, four
hemorphins were suspected: hemorphin-7 or VV-hemorphin-6
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Table 2
Chromatographic parameters (retention time and spectra matching results) of immunoreactive fractions from hemoglobin after 10 min of incu-
bation with lysosomal enzymes
Immunoreactive fractions Spectral analysisa Retention time (min) of synthetic peptide
MA MT Match spectral resultb
Fraction A: 22^24 min 0.779 1.503 H7 22.983
1.221 1.824 VVH6 23.188
Fraction B: 26^27 min 5.066 1.549 VVH7 26.588
Fraction C: 29^30 min 1.332 1.674 LVVH7 29.602
aSpectral analyses were carried out on synthetic peptides puri¢ed under the same chromatographic conditions.
bDeduced from Millenium software after UV comparison with a library spectrum of hemorphins.
MA, match angle; MT, match threshold [18].
Fig. 1. UV absorbance pro¢les (280 nm) of HPLC chromatogram from hemoglobin hydrolysates. One hundred Wl of hydrolysate corresponding
to 1 (A) and 240 (B) min incubation, were applied to a Deltapak C18 column as described in Section 2. VV-hemorphin-7 content was deter-
mined and expressed as pmol of VVH7-i.r. per 100 Wl of hydrolysate.
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in fraction A, VV-hemorphin-7 in fraction B and LVV-hem-
orphin-7 in fraction C. Concerning fraction B, UV spectral
comparison designed actually VV-hemorphin-7 as the VVH7-
i.r. Although the matching result obtained is not optimum
(MAsMT) [14], we could consider the presence of VV-hem-
orphin-7 in this fraction since the only peptide eluted at such
retention time and recognized by IG-C2 antibodies is VV-
hemorphin-7 [17]. The material eluted in fraction C could be
assigned without ambiguity to LVV-hemorphin-7 from both
the retention time and matching result.
The retention time of the VVH7-i.r. in fraction A could lead
us to suspect two hemorphin-related peptides: hemorphin-7
and VV-hemorphin-6. Nevertheless, several arguments al-
lowed us to attribute the VVH7-i.r. to hemorphin-7. First,
better MA and MT values were obtained from spectral com-
parison with hemorphin-7 standard. Then, it has been already
demonstrated that VV-hemorphin-6 was very poorly recog-
nized by IG-C2 antibodies [17]. Finally, the Picotag amino
acid analysis of fraction A revealed the presence of a phenyl-
alanine residue which constitutes the C-terminal amino acid of
hemorphin-7 (data not shown). Accurate molecular weights
predominant in fractions A, B, C (Fig. 3) deduced from the
m/z values of (M+H) by substraction of one mass unit for
the attached proton were 996.6 (A), 1196.6 (B) and 1308.9
(C). This corroborated absolutely the results deduced from
RIA and amino acid analyses and con¢rmed the generation
of hemorphin-7 (fraction A), VV-hemorphin-7 (fraction B)
and LVV-hemorphin-7 (fraction C).
4. Discussion
There is growing evidence that altered protease activities are
involved in many diseases and could potentially generate a
large number of peptides and small proteins. As an example,
among this class of molecules, hemoglobin has been identi¢ed
as a substrate that displays increased proteolysis in Alzheim-
er’s disease cerebellum [5]. The potential for the generation of
biologically active peptides from hemoglobin may have im-
portant implications for the etiology of Alzheimer’s disease.
It could provide at least one link between the disease and
observed aberrant proteolysis that may be a signi¢cant cause
of cellular insult and neuronal degeneration [7]. Moreover,
some studies report increased levels and activities of cathep-
sins D, E and B in the aged brain [25] and it is now believed
that lysosomal alterations, which accompany various pathol-
ogies such as Alzheimer’s disease, could led to the accumula-
tion of peptides. Such changes in the neuronal distribution of
these lysosomal hydrolases correlated with the presence of
hemoglobin in neurons [26] could be related to an increased
hemoglobin degradation leading to the release of bioactive
peptides.
Now, many authors underline the importance of the en-
zyme characterization which could be implicated in the in
vivo release of bioactive peptides derived from hemoglobin.
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Fig. 3. MALDI mass spectrometry of fractions A, B and C. Positive
ions were obtained by MALDI mass spectrometry of fractions A,
B, C. The abundant ions at 997.6 (A), 1197.6 (B) and 1309.9 (C) in-
dicate that A, B, C have predominant molecular weights of 996.6
(hemorphin-7), 1196.6 (VV-hemorphin-7), 1308.9 (LVV-hemorphin-
7) respectively.
Fig. 2. Kinetics of generation of VV-hemorphin-7 immunoreactive
peptides during hemoglobin incubation with lysosomal enzymes.
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Taking into account these considerations, we used puri¢ed
lysosomes in order to examine whether acid hydrolases could
release hemorphins from hemoglobin. By a discontinuous
metrizamide gradient separation, we have been able to isolate
a rat liver lysosomal fraction, free of mitochondrial contam-
inants. Interestingly, an early generation of three hemorphin-
7-related immunoreactive peptides (hemorphin-7, LVV-hem-
orphin-7 and VV-hemorphin-7), mainly represented by hem-
orphin-7, was observed during co-incubation of hemoglobin
with the entire class of lysosomal proteases. Their preference
for a primitive cleavage of hemoglobin at this ‘strategic zone’
[11] may have important implications for the pathobiology of
some diseases. From these ¢ndings, it may be expected that
hemorphins or related peptides might prove to be useful bio-
logical markers of increased levels and activities of proteolytic
enzymes such as cathepsins.
In a previous study, we observed that the co-incubation of
globin with macrophages during 24 h led to the generation of
only one hemorphin: VV-hemorphin-7 [12]. The weak sensi-
tivity of the spectral scan analysis used in this previous study
could explain the detection of only one hemorphin. It was
then also suggested that the protease implicated in the degra-
dation of globin into hemorphin was a cathepsin D-like en-
zyme. This hypothesis was reinforced by the demonstration
that this peptide was generated from hemoglobin by puri¢ed
cathepsin D and exhibited a good stability towards this en-
zyme [13,17]. Moreover, when hemoglobin was incubated with
cathepsin D, no hemorphin-7 was detected neither by UV
spectral analysis nor by RIA [17]. In the present work, we
have followed the generation of three hemorphins. Their levels
reached a plateau at 5 min and, in contrast to the other
studies [12,13,17], they decreased after 1 h. After 2 h no pep-
tides could be detected by UV and only few pmoles of VVH7-
i.r. were detectable.
Incubation of globin with macrophages [12] and hemoglo-
bin with puri¢ed cathepsin D [13,17] when conducted in the
optimal conditions for cathepsin D activity (pH 3.5, 37‡C),
could prevent other proteolytic activities like aminopeptidase
and carboxypeptidase, to be fully expressed. Experimental
conditions used in the present study closely resembles the in
vivo ones (pH 4.5, 37‡C) as reported by Bohley and Seglen
[27]. At such a pH, the battery of proteases classically in-
volved in protein degradation were able to exert their proteo-
lytic activities and might act synergistically to ensure hemo-
globin hydrolysis. At pH 4.5, both aspartic proteases
cathepsins D and L are fully active and may be responsible
for the early release of VV- and LVV-hemorphin-7. The pres-
ence of hemorphin-7 as soon as 1 min of hydrolysis could be
the result of the downstream action of an exopeptidase like
cathepsin C, which is present in mammalian lysosomes [28]. In
fact, this enzyme is reported to act as a diaminopeptidase at a
pH comprised between 4 and 6, and to exhibit signi¢cant
preference for Phe, Leu or Tyr residues at the P1 site and
for Gly or Pro at the P1P cleavage site [29]. In this study,
we observed that neither VV-hemorphin-7 nor hemorphin-7
constituted the ¢nal product of hemoglobin processing.
Nevertheless, the half-life of hemorphin-7 seems to be long
enough to exert an activity for example in the in£ammatory
response [30]. A carboxypeptidase activity could be expected
since a slow degradation of VVH7-i.r. was observed after 1 h
of incubation. The proteolytic pathway involved in hemorphin
generation from hemoglobin by lysosomal enzymes seems to
be the consequence of an ordered process: the polypeptides
released as a result of an early digestion by cathepsin D pro-
vide substrate for exoproteases like cathepsin C and carboxy-
peptidase. Studies using speci¢c enzyme inhibitors should be
useful to explore this proteolytic pathway.
Finally, as a result of that process a large number of pep-
tides is formed from hemoglobin, which accompanies either a
pathology or a physiological state related with an outburst of
protease activity. The components of that ‘tissue-speci¢c pep-
tide pool’ could constitute a part of a general system of pep-
tidergic regulation of tissue homeostasis [2]. However, addi-
tional studies both in laboratories and in the clinics will be
necessary to appraise with accuracy the role of hemorphins in
physiology or pathology.
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